TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05741983

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture (MFx)
Description: The ankle arthroscopy will be a standard procedure. The lesion will be identified, measured and prepared with curettage and soft tissue shaver. Preparation includes debridement of the unstable cartilage and in case of a chondral defect associated with a bone defect, the subchondral cyst is debrided. After debridement, the defect is classified and the lesion size is measured again.The microfracture will be performed with a microfracture awl. In cases of a chondral defect associated with a bone defect (osteochondral defect) the bone lesion must be treated concomitantly. Portal closure will be with steri-strips. All patients will follow the standard postoperative rehabilitation protocol including post op non-weight bearing and range of motion exercises for 6 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture (MFx)
Description: The ankle arthroscopy will be a standard procedure. The lesion will be identified, measured and prepared with curettage and soft tissue shaver. Preparation includes debridement of the unstable cartilage and in case of a chondral defect associated with a bone defect, the subchondral cyst is debrided. After debridement, the defect is classified and the lesion size is measured again.The microfracture will be performed with a microfracture awl. In cases of a chondral defect associated with a bone defect (osteochondral defect) the bone lesion must be treated concomitantly. Portal closure will be with steri-strips. All patients will follow the standard postoperative rehabilitation protocol including post op non-weight bearing and range of motion exercises for 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chondro-Gide®
Description: After the microfracture is performed and before the concomitant treatment of a bony lesion (if present), the defect size will be templated, and the membrane cut into its correct size. The joint is then drained and the membrane will be applied over the defect and stabilised with Fibrin glue. In cases of a osteochondral defect the bone lesion must be treated concomitantly. Once the bone defect has been treated, the Chondro-Gide® membrane is used to cover the site, and to support new cartilage tissue formation at the joint interface. Fluid will be reintroduced, and the stability of the membrane will be confirmed arthroscopically.
Study: NCT04765254

Intervention type: OTHER
Intervention: no intervention as it is an observational study
Description: both groups will be monitored for the disease progress or deterioration and mortality rate

Intervention type: OTHER
Intervention: no intervention as it is an observational study
Description: both groups will be monitored for the disease progress or deterioration and mortality rate
Study: NCT05958459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Exercise
Description: The individuals in the study group will perform home-based eye exercises for at least 1 session (\~30 min.) every day for a total of 12 weeks, after the patient's condition is stable, starting from the 7th day after the surgery. After the initial assessment, participants will be given illustrated brochures describing the exercises and will be taught how to perform the exercises. Whether individuals comply with the exercise program will be closely monitored (by keeping a diary, online meetings and periodically calling individuals). The control group, on the other hand, will not perform any exercise, but will only be evaluated. Eye exercises include eight steps. These; Covering the eyes with the palm of the hand, blinking, lateral gaze, anterior and lateral gaze, rotational gaze, up-down gaze, nasal tip gaze, and near and far gaze.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: no intervention
Study: NCT04539509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: A specific exercise prescription, based on the results of a treadmill test.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill Test
Description: A symptom-limited treadmill test, using the Buffalo Concussion Treadmill Test (BCTT) protocol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Test
Description: A symptom-limited treadmill test, using the Buffalo Concussion Treadmill Test (BCTT) protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Activity monitoring using a Fitbit.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Monitoring
Description: Activity monitoring using a Fitbit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Activity monitoring using a Fitbit.
Study: NCT06249217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good Nights Sleep Program
Description: The Good Nights Sleep Program arm adapts established evidence-based motivational practices to change child and family sleep environments and sleep hygiene practices. At Week 0, participants will provide a comprehensive assessment of sleep environment and sleep hygiene practices and will be issued a Fitbit watch to wear for the duration of the study. At Week 2, participants will receive information about the benefits of good sleep, feedback about their sleep environment and sleep hygiene practices based on the Week 0 assessment data to implement at home, and sleep environment modification items based on participant-identified areas of need (e.g., a fan, sound machine, bedding). At Week 4, families in the Good Nights Sleep Program arm will provide post-intervention assessment data and feedback on the intervention and families in the Waitlist-Control arm can elect to receive the intervention if they choose to.
Study: NCT06567470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIT-013 low dose
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIT-013 high dose
Description: Subcutaneous injection
Study: NCT06285058

Intervention type: DIAGNOSTIC_TEST
Intervention: No interventions
Description: The high-throughput extraction of large amounts of quantitative image features from medical images
Study: NCT06567470

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT05375682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care program
Description: Core Component 1: Fostering Collaboration and Capacity Core Component 2: Streamlined communication process for referrals and care planning Core Component 3: Coordinated Care Conferences
Study: NCT04867226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: participant will be given a Colchicine regimen in a dose of 0.5mg twice daily for 14 days or until symptoms subsides,those with low body weight and develop side effect like diarrhea and vomiting dose will be reduced and supportive treatment will be given .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual care treatment
Description: control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.
Study: NCT05813249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rybelsus Oral Product
Description: Oral Semaglutide
Study: NCT06386666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable fibrous ring sutures
Description: A new disposable fibrous ring suture device developed and produced by 2020 (Beijing) Medical Technology Co., Ltd
Study: NCT04930198

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PeerNaija
Description: All participants (N=50) will receive daily medication reminders and access to the virtual support group on the PEERNaija app. Participants will be randomized to receive a social incentive (n=25) or a social plus financial incentive (n=25), PEER+, and be followed for 24 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PeerNaija
Description: All participants (N=50) will receive daily medication reminders and access to the virtual support group on the PEERNaija app. Participants will be randomized to receive a social incentive (n=25) or a social plus financial incentive (n=25), PEER+, and be followed for 24 weeks.
Study: NCT06568250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAMP program
Description: The RAMP program is a 12-week virtual program consisting of an individual session (50 minutes) with a Whole Health Coach followed by 11 weekly interactive group sessions (90 minutes each) with pre-recorded expert led education videos, mind-body skill training and practice, and facilitated discussions.
Study: NCT05555186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BWL classrooms (Experimental)
Description: Adolescents in the BWL classrooms will be exposed to the circadian stimulating bright light (600-1000lx) to maintain alertness. The programming of the LED lighting system in the intervention group (BWL) will be tuned to provide equal stimuli to the cone and melanopsin-containing photoreceptors measured at the eye height (1.2 m above floor level for sitting position) approximately in the range 4500 -5500 K (cool white light) or between 600 and 1000 lx.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DWL classrooms (Comparison)
Description: Participants in DWL classrooms will receive conventional light from the same kind of equipment as used for the intervention group, only not applying high circadian stimulation(300lx). In order to replicate conventional lighting in the classrooms, the programming of the new LED lighting system in the control group (DWL) will meet the minimum requirements according to EN12464-181, or at least 300 lx measured at table height for a light source rated at 3000 K (warm white light).
Study: NCT05355831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation
Description: See arm/group description

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: See arm/group description
Study: NCT04624841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: 2.5-7.5 mg (0.05 mg/kg) injection
Study: NCT02968641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lonafarnib
Description: antiviral farnesyltransferase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lonafarnib
Description: antiviral farnesyltransferase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lonafarnib
Description: antiviral farnesyltransferase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: CYP 3A4 inhibitor, lonafarnib booster

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: CYP 3A4 inhibitor, lonafarnib booster
Study: NCT06521281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chan-Chuang qigong
Description: Twice daily, every 15 minutes Chan-Chuang qigong
Study: NCT06204276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Asymmetrical high-flow nasal cannula
Description: Asymmetrical high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and inspired oxygen fraction (FiO2) will be adjusted to maintain oxygen saturation by pulse oximetry (SpO2) \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Conventional high-flow nasal cannula
Description: Conventional high-flow nasal cannula will be set at 40 and 60 L/min in a random order. Temperature will be set at 37 degree celsius and FiO2 will be adjusted to maintain SpO2 \>/= 94% in acute hypoxemic patients and between 92-94% in acute hypercapnic COPD patients
Study: NCT05292469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive approach to hypertension management
Description: Trained health workers will review blood pressure (BP) logs and provide treatment. The patients will receive a BP lowering informational package, BP monitoring device and log book and pill-box and medication table. The participants will receive monthly home visits (6 visits) to discuss hypertension and ways to manage it. They will be encouraged to identify problems and developing an action plan to solve them. The participants will be encouraged to set behavioral goals. The follow up visits will review the progress made in implementing action plan and goals set and updating them. Review BP logs and facilitate tailored discussion on topics based on problems faced by participants on barriers to medication adherence, physical activity, weight management or diet. The family members will be involved and be accountable in supporting the patients in achieving the action plans.
Study: NCT04909125

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated radiotherapy VS Standard/Conventional fractionation radiotherapy
Description: The purpose of this study is to investigate toxicity following standard conventional fractionation versus moderately hypofractionated radiotherapy to the breast, chest wall and regional lymph nodes

Intervention type: RADIATION
Group type: OTHER
Intervention: Hypofractionated radiotherapy VS Standard/Conventional fractionation radiotherapy
Description: The purpose of this study is to investigate toxicity following standard conventional fractionation versus moderately hypofractionated radiotherapy to the breast, chest wall and regional lymph nodes
Study: NCT05439759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 1: Training visual sensitivity
Description: Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 2: Training spatial integration
Description: Spatial integration involves what the investigators refer to as mid-level vision. Spatial integration is a concern in developing a PRL since an area of the visual periphery that is best suited to discriminate a simple visual feature may not be appropriate to integrate information across objects, such as in reading or recognizing facial identity or expression. The investigators address this issue with a targeted spatial integration training approach developed by MPI Seitz and based on contour integration tasks used in previous PL studies to train mid-level visual processes. Target stimuli consist of contours formed by spaced Gabors. The difficulty is manipulated by varying orientation jitter of Gabors. Several optotypes will be included to promote generalization, including shapes and facial expressions.
Study: NCT04586855

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Ultrasound
Description: To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Transnasal Fiberoptic Laryngoscopy
Description: To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
Study: NCT05923281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 0.2 mg/day (once daily)
Description: K-877 0.2mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 0.4 mg/day (once daily)
Description: K-877 0.2mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (once daily)
Description: Placebo tablet
Study: NCT06444282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emergency Care Action Plan
Description: An Emergency Care Action Plan (ECAP) is a brief, pre-populated summary of suggested emergency management for children with medical complexity, embedded in a patient's electronic health record for access by providers in an emergency. Patients/families will have digital access to the ECAP and be given a paper copy. The patient's care team and caregiver(s) (parent/legal guardian) will collaborate to create an individualized ECAP containing the following content: caregiver contact information, patient summary, anticipated emergency presentations with suggested management, problem list (emergency relevant only), medication list, technology dependence, baseline important physical exam findings, baseline vital signs, allergies, advance directive information, contact information for established care providers, and other important information.
Study: NCT05387291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention group will undergo an education program related to the circumcision process for the child's relatives/guardians.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: The control group will receive the usual intervention of the center.
Study: NCT05846724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Lenvatinib
Description: single-arm study of pembrolizumab plus lenvatinib
Study: NCT05439759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 3: Training spatial attention
Description: The investigators will implement a task structure that requires participants to alternate between holding and switching attention and making targeted eye movements. The basic task is to press a key whenever a red-circle appears in a series of other colored-circles, with a target presented every 2 to 4s. Participants must maintain vigilance for relatively long periods, detect objects in the near periphery, switch attention based upon exogenous and endogenous cues, and make eye- movements to move areas of spared vision to those locations. These are aspects of attention and eye movements not incorporated in Conditions 1 and 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 4: Combination training
Description: Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision,Condition 4 combines the elements of Conditions 1-3.
Study: NCT05512715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radioactive iodine
Description: radioactive iodine 15mci

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radioactive iodine
Description: radioactive iodine 15mci
Study: NCT05880628

Intervention type: OTHER
Intervention: datas of medical record.
Description: Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique~* Efficacity (sclerose of the lesion)
Study: NCT05069428

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramelteon 8mg
Description: administered crushed, orally at 20:30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon 8mg
Description: administered crushed, orally at 20:30
Study: NCT05078801

Intervention type: PROCEDURE
Intervention: Endoscopic drainage
Description: ERCP and/or EUS-guided biliary drainage

Intervention type: PROCEDURE
Intervention: Percutaneous transhepatic biliary drainage
Description: US or CT-guided percutaneous drainage
Study: NCT05324709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Based Stress Management Program
Description: Yoga-based stress management program is applied to the intervention group.
Study: NCT06120452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rael Miracle Clear Complete Acne Serum
Description: This acne serum contains the following ingredients:~1.5% Salicylic acid. 2% Niacinamide. 0.5% Zinc Pyrrolidone Carboxylic Acid (PCA). Hyaluronic Acid.
Study: NCT06003491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-articular Cages
Description: Using reduction using posterior intra-articular distraction and fusion technique with cages.
Study: NCT04953481

Intervention type: OTHER
Intervention: survey
Description: The general information, home care status and functional status of ALS patients and family caregivers were collected.
Study: NCT06640244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: To be used by all participants throughout the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: To be used by all participants throughout the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: To be used by all participants throughout the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: To be used by all participants throughout the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: To be used by all participants throughout the study
Study: NCT05813249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozempic Injectable Product
Description: Subcutaneous Semaglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocopherol and/or Actos
Description: Vitamin E and/or Pioglitazone
Study: NCT05993832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: input cue
Description: The object is labelled with 1) gaze only; 2) novel label only; or 3) conflicting gaze and novel label
Study: NCT06640244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic product G18
Description: Cosmetic face care product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic product N70
Description: Cosmetic face care product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic product D79
Description: Cosmetic face care product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic product E84
Description: Cosmetic face care product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cosmetic product C68
Description: Cosmetic face care product
Study: NCT05313503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: We propose a type of KD named MAD (Modified Atkins Diet) characterized by the following percentages of macronutrients: 65% fats, 27% proteins and 8% carbohydrates.
Study: NCT05762510

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GMCN-508B (LentiRed)
Description: LentiRed Drug Product is administered by intravenous infusion following myeloablative conditioning with busulfan.
Study: NCT04711278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mask-wearing hypnosis
Description: Virtual mask will be worn by patients before and during surgery of Hallux valgus to realize hypnosis.~Virtual mask with 2 types of voice: female voice and male voice. Several types of image or music to choice by patient.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Without hypnosis
Description: No hypnosis during surgery of Hallux valgus.